Zhang L - Search Results

1

Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy.

Long H, Jia Q, Wang L, Fang W, Wang Z, Jiang T, Zhou F, Jin Z, Huang J, Zhou L, Hu C, Wang X, Zhang J, Ba Y, Gong Y, Zeng X, Zeng D, Su X, Alexander PB, Wang L, Wang L, Wan YY, Wang XF, Zhang L, Li QJ, Zhu B. Long H, et al. Among authors: zhang l, zhang j. Cancer Cell. 2022 Jun 13;40(6):674-693.e7. doi: 10.1016/j.ccell.2022.04.018. Epub 2022 May 19. Cancer Cell. 2022. PMID: 35594863 Free article.

2

PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy.

Fang W, Huang Y, Gu W, Gan J, Wang W, Zhang S, Wang K, Zhan J, Yang Y, Huang Y, Zhao H, Zhang L. Fang W, et al. Among authors: zhang l, zhang s. Transl Lung Cancer Res. 2020 Aug;9(4):1258-1267. doi: 10.21037/tlcr-20-141. Transl Lung Cancer Res. 2020. PMID: 32953503 Free PMC article.

3

Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer.

Liu H, Ma Y, Yang C, Xia S, Pan Q, Zhao H, Fang W, Chen X, Zhang Y, Zou B, Li Q, Wan Y, Chen H, Tang Y, Zhao J, Weng D, Xia L, Zhang L, Xia J. Liu H, et al. Among authors: zhang l, zhang y. Clin Transl Immunology. 2020 Oct 9;9(10):e1154. doi: 10.1002/cti2.1154. eCollection 2020. Clin Transl Immunology. 2020. PMID: 33072320 Free PMC article.

4

A Phase I Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid Tumors.

Ma Y, Fang W, Zhao H, Bathena SP, Tendolkar A, Sheng J, Zhang L. Ma Y, et al. Among authors: zhang l. Oncologist. 2021 Apr;26(4):e549-e566. doi: 10.1002/onco.13577. Epub 2020 Nov 11. Oncologist. 2021. PMID: 33105036 Free PMC article. Clinical Trial.

5

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study.

Zhao S, Zhang Z, Fang W, Zhang Y, Zhang Z, Hong S, Ma Y, Zhou T, Yang Y, Huang Y, Zhao H, Zhang L. Zhao S, et al. Among authors: zhang l, zhang z, zhang y. Front Oncol. 2020 Nov 10;10:587849. doi: 10.3389/fonc.2020.587849. eCollection 2020. Front Oncol. 2020. PMID: 33244458 Free PMC article.

6

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma.

Bai H, Duan J, Li C, Xie W, Fang W, Xu Y, Wang G, Wan R, Sun J, Xu J, Wang X, Fei K, Zhao Z, Cai S, Zhang L, Wang J, Wang Z. Bai H, et al. Among authors: zhang l. J Immunother Cancer. 2020 Dec;8(2):e001315. doi: 10.1136/jitc-2020-001315. J Immunother Cancer. 2020. PMID: 33303576 Free PMC article.

7

MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis.

Fang W, Zhou H, Shen J, Li J, Zhang Y, Hong S, Zhang L. Fang W, et al. Among authors: zhang l, zhang y. ESMO Open. 2020;5(1):e000614. doi: 10.1136/esmoopen-2019-000614. Epub 2020 Sep 30. ESMO Open. 2020. PMID: 33551066 Free PMC article. No abstract available.

8

Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy.

He LN, Zhang X, Li H, Chen T, Chen C, Zhou Y, Lin Z, Du W, Fang W, Yang Y, Huang Y, Zhao H, Hong S, Zhang L. He LN, et al. Among authors: zhang l, zhang x. Front Oncol. 2021 Jan 19;10:621329. doi: 10.3389/fonc.2020.621329. eCollection 2020. Front Oncol. 2021. PMID: 33552993 Free PMC article.

9

Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer.

Luo Y, Yang Y, Peng P, Zhan J, Wang Z, Zhu Z, Zhang Z, Liu L, Fang W, Zhang L. Luo Y, et al. Among authors: zhang l, zhang z. Transl Lung Cancer Res. 2021 Jan;10(1):128-142. doi: 10.21037/tlcr-20-812. Transl Lung Cancer Res. 2021. PMID: 33569299 Free PMC article.

10

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer.

Fang W, Jin H, Zhou H, Hong S, Ma Y, Zhang Y, Su X, Chen L, Yang Y, Xu S, Liao Y, He Y, Zhao H, Huang Y, Gao Z, Zhang L. Fang W, et al. Among authors: zhang l, zhang y. Mol Cancer. 2021 Feb 23;20(1):37. doi: 10.1186/s12943-021-01331-9. Mol Cancer. 2021. PMID: 33622313 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

124,452 results

Search Page